Florida Medicaid
Executive Summary
Florida Medicaid's preferred drug list will include Pfizer's Zoloft, Forest's Lexapro and GlaxoSmithKline's Paxil CR, Wellbutrin XL and Lamictal after the manufacturers renegotiated prices for the mental health products. The drugs were not initially recommended for inclusion by the Florida pharmacy & therapeutics committee under revisions to the Medicaid PDL (1"The Pink Sheet" July 11, 2005, p. 11). Wyeth's Effexor XR and Lilly's antidepressants (Cymbalta, Prozac Weekly, Sarafem) and antipsychotics (Zyprexa and Symbyax) are among the products that will require prior authorization...
You may also be interested in...
Lilly’s Zyprexa, Cymbalta Will Be Dropped From Florida Medicaid Drug List
Florida Medicaid will reconsider the status of GlaxoSmithKline's Paxil, Forest's Lexapro and Pfizer's Zoloft on the state's preferred drug list in September after awarding the antidepressants conditional placement on the PDL
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.